secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001662774-25-000031
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quince may end Phase 3 NEAT enrollment early in June 2025 to align cash runway with topline results in early 2026
--------------------------------------------------------------------------------

- 63 participants enrolled to date (56 in primary analysis population ages 6–9); original target was 86.
- Early enrollment conclusion by end of June would provide ~80% power for primary endpoint.
- Cash and investments $31.6M; net loss Q1 2025 of $15.0M ($0.34 per share).
- Topline results expected early 2026; NDA/MAA submissions planned H2 2026 if positive.
- All 19 study sites activated; slower enrollment cited due to challenging academic site environment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000166277425000031/0001662774-25-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000166277425000031/qncx-20250513.htm
  HTML page:      https://secwatch.observer/filing/0001662774-25-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer